IVAC_W_bre1_uID + IVAC_W_bre1_uID/IVAC_M_uID
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Conditions
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Trial Timeline
Oct 1, 2016 → May 17, 2023
NCT ID
NCT02316457About IVAC_W_bre1_uID + IVAC_W_bre1_uID/IVAC_M_uID
IVAC_W_bre1_uID + IVAC_W_bre1_uID/IVAC_M_uID is a phase 1 stage product being developed by BioNTech for Breast Cancer (Triple Negative Breast Cancer (TNBC)). The current trial status is completed. This product is registered under clinical trial identifier NCT02316457. Target conditions include Breast Cancer (Triple Negative Breast Cancer (TNBC)).
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer (Triple Negative Breast Cancer (TNBC)) were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02316457 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer (Triple Negative Breast Cancer (TNBC))